- GBI & PARTNERS
- Kintor puts hair loss AR antagonist on JD.com
Kintor puts hair loss AR antagonist on JD.com
China-based Kintor Pharmaceutical Ltd (9939.HK) is set to market its AR antagonist KX-826 (pyrilutamide), a treatment for androgenetic alopecia (male pattern baldness), on Chinese e-commerce giant JD.com’s online drug retail portal yiyaojd.com. Kintor will also recruit more than 100 salespeople to support sales of the product.
Kintor is a clinical-stage biotech covering research and development, manufacturing and sales of innovative small molecules against prostate, breast, and liver cancers. Another lead drug candidate, GT0918 (proxalutamide), is subject to a Phase III clinical study in metastatic castration-resistant prostate cancer (mCRPC) in China, and a Phase II study in breast cancer in the US. The company completed an initial public offering (IPO) of 92,347,500 shares to the Hong Kong Stock Exchange (HKSE) in May this year, raising HKD 1.86 billion (USD 240 million).